Protocols
Research Stage
BPC-157 underwent two distinct regulatory events in 2026: the FDA removed it from the Category 2 significant-safety-risk list in April, and the Pharmacy Compounding Advisory Committee voted in favour of adding it to the 503A Bulks List in July. Neither event legalises compounding. The PCAC vote is non-binding, and formal rulemaking takes a minimum of 12–18 months.
October 1, 2026
·
11 min read
Protocols
Research Stage
Both failure modes are documented and occurring simultaneously in 2026. Independent laboratory testing of black-market peptide vials has found products with active-ingredient concentrations up to double the labeled dose — a direct overdose risk — while other vials from the same market contained none of the advertised peptide at all. Neither outcome is detectable without analytical chemistry.
September 30, 2026
·
11 min read
Protocols
Research Stage
A 2026 Scientific Reports study and a companion IJMS critical review document that BPC-157 attenuates skeletal muscle ischemia-reperfusion injury in rats by reducing malondialdehyde, upregulating superoxide dismutase and catalase activity, suppressing caspase-3-mediated apoptosis, and preserving microvascular endothelial integrity — mechanisms that converge with the Yuan 2026 IJMS review's account of BPC-157's pro-angiogenic and cytoprotective signalling across tissue types.
September 28, 2026
·
10 min read
Protocols
Research Stage
Tirzepatide produces meaningfully greater weight loss than semaglutide. The 2025 SURMOUNT-5 head-to-head RCT found body-weight reductions of 20 percent versus 14 percent at 72 weeks in adults with obesity without type 2 diabetes. GI-related discontinuations were lower with tirzepatide. Pooled meta-analytic data show elevated SAE rates in type 2 diabetes populations but comparable rates in the obesity-only SURMOUNT-5 cohort.
September 28, 2026
·
11 min read
Protocols
Research Stage
Gray-market retatrutide users achieve less than half the weight loss of trial participants, based on an August 2026 EHR preprint of 652 patients that found 7·2% mean body-weight reduction at 6–12 months versus 15·5% in a matched trial cohort, with tachycardia rates 2·88 times higher in the gray-market group.
September 24, 2026
·
11 min read
Protocols
Research Stage
The FAERS record for BPC-157 is thin but not empty. The FDA's July 2026 PCAC briefing cites compounded BPC-157 case reports, with the only controlled human study documenting headache and flatulence after rectal administration. Serious adverse events in the broader compounded peptide category include rhabdomyolysis, sympathomimetic toxidrome, and posterior reversible encephalopathy syndrome; per-compound attribution is limited by spontaneous-reporting quality.
September 23, 2026
·
11 min read